WT1

• About this biomarker
• Introduction to our products
• Why choose our products
• Product for WT1
• Associated products
• Related publications

The Wilms’ tumour gene (WT1) is a tumour suppressor gene coding for a zinc-finger transcription factor, located on the short arm of chromosome 11p13, originally identified for its involvement in the pathogenesis of Wilms’ tumour, a renal neoplasm of children [Sugiyama H et al. Int J Hematol. 2001].

Depending on the cellular or chromosomal context, WT1 protein can act either as a transcriptional activator or repressor, and has both physiological and pathological functions especially in oncogenesis.

Approximately half of all AML adult patients lack clonal chromosome aberrations at diagnosis, and although this group has an intermediate prognosis, only 40% are long-term survivors. There is therefore a clear need for specific molecular markers to improve diagnosis, prognosis and follow-up of this group of AML patients.

WT1 has been shown to be highly expressed in several hematopoietic tumors including AML [Sugiyama H et al. Int J Hematol. 2001]. Moreover, a recent study reports that early decrease of WT1 copy number in peripheral blood predicts better outcome and should be considered in the management of AML [Gianfaldoni G et al. Haematologica. 2010].

A previous evaluation of WT1 gene expression reported that WT1 transcripts provide a reliable indicator that may be used for Minimal Residual Disease monitoring in AML with normal karyotype [Ostergaard M et al. British J. Haematol. 2004].

The WT1 ProfileQuant® kit includes specific plasmids and primers and probe mixes for WT1 and ABL.
These components have been validated together in the context of a collaborative study led by a group of experts from the European LeukemiaNet (ELN) consortium [Cilloni D et al. J. Clin. Oncol. (JCO) 2009].

WT1 ProfileQuant® kit uses Real Time Quantitative PCR to quantify WT1 gene expression relative to ABL control gene. With the objective to provide a standardized assay with the highest performance, IPSOGEN contributed to an international multicenter study coordinated by the European LeukemiaNet (ELN) consortium.

The WT1  ProfileQuant® kit, resulting from this collaboration, incorporates a set of primers & probe that was found to outperform the other 8 assays tested in this multicenter study.

Why choose WT1 ProfileQuant® Kits?

• Developed and optimized by the European LeukemiaNet (ELN) consortium

• Calibrated and sensitive quantification of WT1 gene expression, normalized with ABL control gene expression (results in NCN)

• Product manufactured under ISO 13485 certification ensuring optimal quality control and full traceability

Wilms' tumor gene WT1: its oncogenic function and clinical application.
Int J Hematol. 2001
Authors:Sugiyama H et al. 

Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.
Haematologica. 2010
Authors:Gianfaldoni G et al. 

WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
British J. Haematol. 2004
Authors: Ostergaard M et al.

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study. *
J Clin Oncol. 2009
Authors: Cilloni et al.